Events
Dissertation: Giorgio Turconi
Opponent: Professor Deniz Kirik, Lund University
HiLIFE Webinar: Ryan Flynn
Ryan is a New Jersey native who completed his undergraduate training at MIT, where he worked in the lab of Phillip Sharp on small noncoding RNA biology. Subsequently he moved to Stanford where he completed his M.D. and Ph.D. with Howard Chang developing methods to study RNA-protein interactions. From this work, he won the Weintraub Graduate Student Award. As a post-doc he changed fields to learn both chemistry and glycobiology with Carolyn Bertozzi at Stanford as a Damon Runyon Cancer Research Postdoctoral Fellow. At the beginning of 2021, the Flynn Lab opened at Boston Children’s Hospital in the Stem Cell Program and the Department of Stem Cell and Regenerative Biology at Harvard University. The Flynn Lab is currently focused on advancing methods and mechanisms surrounding the glycoRNA molecule, which operates at the interface of RNA biology and the secretory pathway.
Lab Website: http://www.rafrna.com/
Twitter: @raflynn5
Welcome to this exciting seminar!
Selected publications:
Ryan A Flynn , Kayvon Pedram, Stacy A Malaker, Pedro J Batista, Benjamin A H Smith, Alex G Johnson, Benson M George, Karim Majzoub, Peter W Villalta, Jan E Carette, Carolyn R Bertozzi. Small RNAs are modified with N-glycans and displayed on the surface of living cells. Cell 2021 Jun 10;184(12):3109-3124.e22.doi: 10.1016/j.cell.2021.04.023.
Ryan A Flynn, Julia A Belk, Yanyan Qi , Yuki Yasumoto, Jin Wei, Mia Madel Alfajaro, Quanming Shi, Maxwell R Mumbach, Aditi Limaye, Peter C DeWeirdt, Cameron O Schmitz, Kevin R Parker, Elizabeth Woo, Howard Y Chang, Tamas L Horvath, Jan E Carette, Carolyn R Bertozzi, Craig B Wilen, Ansuman T Satpathy. Discovery and functional interrogation of SARS-CoV-2 RNA-host protein interactions. Cell 2021 Apr 29;184(9):2394-2411.e16. doi: 10.1016/j.cell.2021.03.012.
KLIINISEN PATOLOGIAN NYKYNÄKYMIÄ
Katriina Peltola
iCAN Science Seminar by Dr. Saar Gill
Dr. Gill obtained his medical degree and Ph.D in immunology from the University of Melbourne, and trained in hematology at St Vincent’s Hospital, the Royal Melbourne Hospital and the Peter MacCallum Cancer Centre. In 2008 he moved to the United States, first to pursue a post-doctoral fellowship in cellular therapy at Stanford University, and then in 2011 to the University of Pennsylvania where he is now an associate professor of medicine. Dr. Gill’s clinical practice is in leukaemia and bone marrow transplantation. He has led clinical trials of chimeric antigen receptor (CAR) T cells for chronic and acute leukemias. Dr. Gill’s research laboratory focuses on the interface between adoptive cellular therapy and genetic engineering.
https://www.med.upenn.edu/cci/gilllab
If you would like to have a meeting with Dr. Gill, please contact Satu Mustjoki (satu.mustjoki@helsinki.fi) or Francesca De Lorenzo (francesca.delorenzo@helsinki.fi)
Recent publications:
Gill SI, Vides V, Frey NV, Hexner E, Metzger S, O'Brien M, Hwang WT, Brogdon JL, Davis MM, Fraietta JA, Gaymon A, Gladney WL, Lacey SF, Lamontagne A, Mato AR, Maus MV, Melenhorst JJ, Pequignot E, Ruella M, Shestov MA, Byrd JC, Schuster SJ, Siegel DL, Levine BL, June CH, Porter DL. Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia. Blood Adv. 2022 Mar 29:bloodadvances.2022007317.
Singh N*, Frey NV*, Engels B*, Barrett DM, Shestova O, Ravikumar P, Cummins KD, Lee YG, Pajarillo R, Chun I, Shyu A, Highfill SL, Price A, Zhao L, Peng L, Granda B, Ramones M, Lu XM, Christian DA, Perazzelli J, Lacey SF, Roy NH, Burkhardt JK, Colomb F, Damra M, Abdel-Mohsen M, Liu T, Liu D, Standley DM, Young RM, Brogdon JL, Grupp SA, June CH, Maude SL*, Gill S*, Ruella M*. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. Nat Med. 2021 May;27(5):842-850. *equal contribution
Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, Schmierer M, Gabrusiewicz K, Anderson NR, Petty NE, Cummins KD, Shen F, Shan X, Veliz K, Blouch K, Yashiro-Ohtani Y, Kenderian SS, Kim MY, O'Connor RS, Wallace SR, Kozlowski MS, Marchione DM, Shestov M, Garcia BA, June CH, Gill S. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020 Aug;38(8):947-953.
Singh N*, Lee YG*, Shestova O, Ravikumar P, Hayer KE, Hong SJ, Lu XM, Pajarillo R, Agarwal S, Kuramitsu S, Orlando EJ, Mueller KT, Good CR, Berger SL, Shalem O, Weitzman MD, Frey NV, Maude SL, Grupp SA, June CH, Gill S*, Ruella M*. Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction. Cancer Discov. 2020 Apr;10(4):552-567. *equal contribution
Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, Aljanahi AA, Schreeder D, Klichinsky M, Shestova O, Kozlowski MS, Cummins KD, Shan X, Shestov M, Bagg A, Morrissette JJD, Sekhri P, Lazzarotto CR, Calvo KR, Kuhns DB, Donahue RE, Behbehani GK, Tsai SQ, Dunbar CE, Gill S. Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. Cell. 2018 May 31;173(6):1439-1453.e19.
Dissertation: Saana Mönkäre
Opponent: docent Maria Johansson-Soller, Karolinska University Hospital